Effectivity and Safety of Febuxostat in Reducing Serum Urate in Gout Patients With Chronic Kidney Disease: A Prospective Multicenter ULTRA Registry Study
Study context
- Population
- Gout patients on febuxostat in the ULTRA registry, November 2021 to December 2023, with ≥1-year follow-up112 analysed
- Participants
- 405 patients
- Exposure
- Gout patients with chronic kidney disease (CKD) vs normal renal function on febuxostat
- Outcome
- Longitudinal changes in SU levels and febuxostat dosage by renal function
- Follow-up
- Baseline, 6 and 12 months
Methodological detailsmulticentre, registry (ULTRA)
- Multicentre
- Registry (ULTRA)
Main finding
As reported in the abstract
SU level · 6 months
P = 0.001
Observational data: associations, not effects.
Further findings
SU level · 12 months
P = 0.04
Febuxostat dose · 6 months · not statistically significant
P = 0.11
Febuxostat dose · 12 months · not statistically significant
P = 0.06
SU < 6 mg/dL achieved · 6 months
P = 0.01
Original publication
Effectivity and Safety of Febuxostat in Reducing Serum Urate in Gout Patients With Chronic Kidney Disease: A Prospective Multicenter ULTRA Registry Study. J Rheumatol. Published 1 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →